Empyrean Capital Partners’s ProKidney PROK Stock Holding History

Empyrean Capital Partners’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500,000	Closed	-$4.97M	–	133
2022 Q2	$4.97M	Hold	500,000	–	–	0.16%	112
2022 Q1	$4.95M	Hold	500,000	–	–	0.11%	127
2021 Q4	$4.95M	Hold	500,000	–	–	0.13%	119
2021 Q3	$4.9M	Hold	500,000	–	–	0.11%	126
2021 Q2	$5.05M	Buy	+500,000	New	+$5.05M	0.12%	133

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Empyrean Capital Partners's PROK Position: Q3 2022 in Review

Empyrean Capital Partners sold out of ProKidney (PROK) in Q3 2022, closing a stake of 500,000 shares — an estimated $4.97M sold.

Empyrean Capital Partners first reported a position in PROK in Q2 2021 and held it in 5 quarters. The position peaked at $5.05M in Q2 2021. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

Empyrean Capital Partners reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
Empyrean Capital Partners sold 500,000 ProKidney shares in Q3 2022, an estimated $4.97M.
Empyrean Capital Partners first reported a position in ProKidney in Q2 2021 and held it in 5 quarters.
Empyrean Capital Partners's ProKidney position peaked at $5.05M in Q2 2021.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on Empyrean Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.